A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab
A 72-year-old man with a 10-year history of coronary heart disease started evolocumab treatment once a month after developing excess myalgia due to therapy with a 3-hydroxy-methylglutaryl CoA reductase inhibitor. No side effects such as myalgia symptoms had been reported during the first 14 months o...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2020/3281626 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849696307673825280 |
|---|---|
| author | Ikuo Inoue Yasuhiro Takenaka Yoshitora Kin Satoshi Yamazaki Yuichi Ikegami Daigo Saito Akira Shimada |
| author_facet | Ikuo Inoue Yasuhiro Takenaka Yoshitora Kin Satoshi Yamazaki Yuichi Ikegami Daigo Saito Akira Shimada |
| author_sort | Ikuo Inoue |
| collection | DOAJ |
| description | A 72-year-old man with a 10-year history of coronary heart disease started evolocumab treatment once a month after developing excess myalgia due to therapy with a 3-hydroxy-methylglutaryl CoA reductase inhibitor. No side effects such as myalgia symptoms had been reported during the first 14 months of evolocumab treatment; however, he suddenly presented with acute severe thrombocytopenia following the 14th treatment. His platelet count continued to decrease to a nadir of 1,000/μL. His platelet-associated immunoglobulin G level had elevated to 790 ng/107 cells. He started receiving a combination of steroid therapy, high-dose immunoglobulin therapy, and platelet transfusions, but the first-line therapy was ineffective. He was subsequently treated with a thrombopoietin receptor agonist, and his platelet count recovered to 250,000/μL. |
| format | Article |
| id | doaj-art-cb300bb50d404fc2bf5e6b4e2a5e1533 |
| institution | DOAJ |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-cb300bb50d404fc2bf5e6b4e2a5e15332025-08-20T03:19:29ZengWileyCase Reports in Hematology2090-65602090-65792020-01-01202010.1155/2020/32816263281626A Sudden Onset of Severe Thrombocytopenia While Using EvolocumabIkuo Inoue0Yasuhiro Takenaka1Yoshitora Kin2Satoshi Yamazaki3Yuichi Ikegami4Daigo Saito5Akira Shimada6Department of Endocrinology and Diabetes, Faculty of Medicine, Saitama Medical University, 38 Morohongo, Moroyama, Iruma, Saitama 350-0495, JapanDepartment of Endocrinology and Diabetes, Faculty of Medicine, Saitama Medical University, 38 Morohongo, Moroyama, Iruma, Saitama 350-0495, JapanDepartment of Internal Medicine, Fukaya Red Cross Hospital, 5-8-1 Kamishibatyohnishi, Fukaya, Saitama 366-0052, JapanKumagaya-geka Hospital, 3811-1 Sayata, Kumagaya, Saitama 360-0023, JapanDepartment of Endocrinology and Diabetes, Faculty of Medicine, Saitama Medical University, 38 Morohongo, Moroyama, Iruma, Saitama 350-0495, JapanDepartment of Endocrinology and Diabetes, Faculty of Medicine, Saitama Medical University, 38 Morohongo, Moroyama, Iruma, Saitama 350-0495, JapanDepartment of Endocrinology and Diabetes, Faculty of Medicine, Saitama Medical University, 38 Morohongo, Moroyama, Iruma, Saitama 350-0495, JapanA 72-year-old man with a 10-year history of coronary heart disease started evolocumab treatment once a month after developing excess myalgia due to therapy with a 3-hydroxy-methylglutaryl CoA reductase inhibitor. No side effects such as myalgia symptoms had been reported during the first 14 months of evolocumab treatment; however, he suddenly presented with acute severe thrombocytopenia following the 14th treatment. His platelet count continued to decrease to a nadir of 1,000/μL. His platelet-associated immunoglobulin G level had elevated to 790 ng/107 cells. He started receiving a combination of steroid therapy, high-dose immunoglobulin therapy, and platelet transfusions, but the first-line therapy was ineffective. He was subsequently treated with a thrombopoietin receptor agonist, and his platelet count recovered to 250,000/μL.http://dx.doi.org/10.1155/2020/3281626 |
| spellingShingle | Ikuo Inoue Yasuhiro Takenaka Yoshitora Kin Satoshi Yamazaki Yuichi Ikegami Daigo Saito Akira Shimada A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab Case Reports in Hematology |
| title | A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab |
| title_full | A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab |
| title_fullStr | A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab |
| title_full_unstemmed | A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab |
| title_short | A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab |
| title_sort | sudden onset of severe thrombocytopenia while using evolocumab |
| url | http://dx.doi.org/10.1155/2020/3281626 |
| work_keys_str_mv | AT ikuoinoue asuddenonsetofseverethrombocytopeniawhileusingevolocumab AT yasuhirotakenaka asuddenonsetofseverethrombocytopeniawhileusingevolocumab AT yoshitorakin asuddenonsetofseverethrombocytopeniawhileusingevolocumab AT satoshiyamazaki asuddenonsetofseverethrombocytopeniawhileusingevolocumab AT yuichiikegami asuddenonsetofseverethrombocytopeniawhileusingevolocumab AT daigosaito asuddenonsetofseverethrombocytopeniawhileusingevolocumab AT akirashimada asuddenonsetofseverethrombocytopeniawhileusingevolocumab AT ikuoinoue suddenonsetofseverethrombocytopeniawhileusingevolocumab AT yasuhirotakenaka suddenonsetofseverethrombocytopeniawhileusingevolocumab AT yoshitorakin suddenonsetofseverethrombocytopeniawhileusingevolocumab AT satoshiyamazaki suddenonsetofseverethrombocytopeniawhileusingevolocumab AT yuichiikegami suddenonsetofseverethrombocytopeniawhileusingevolocumab AT daigosaito suddenonsetofseverethrombocytopeniawhileusingevolocumab AT akirashimada suddenonsetofseverethrombocytopeniawhileusingevolocumab |